Trader consensus on Polymarket reflects an 84% implied probability for no new WHO-designated COVID variant of concern (VOC) before 2027, driven by the absence of alarming signals despite the rapid spread of Omicron sublineage BA.3.2—nicknamed Cicada—which WHO classified as a variant under monitoring (VUM) in December 2025 rather than elevating to VOC status. Recent April 2026 surveillance from ECDC and WHO shows Cicada in over 30 countries and U.S. states, with high spike mutations suggesting immune evasion, yet no evidence of heightened severity, hospitalizations, or vaccine failure amid widespread population immunity from prior infections and boosters. Overall SARS-CoV-2 cases remain low, underscoring effective genomic monitoring; a VOC upgrade would require substantial shifts in transmissibility or public health impact.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트예
$233,739 거래량
$233,739 거래량
예
$233,739 거래량
$233,739 거래량
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
마켓 개설일: Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...Trader consensus on Polymarket reflects an 84% implied probability for no new WHO-designated COVID variant of concern (VOC) before 2027, driven by the absence of alarming signals despite the rapid spread of Omicron sublineage BA.3.2—nicknamed Cicada—which WHO classified as a variant under monitoring (VUM) in December 2025 rather than elevating to VOC status. Recent April 2026 surveillance from ECDC and WHO shows Cicada in over 30 countries and U.S. states, with high spike mutations suggesting immune evasion, yet no evidence of heightened severity, hospitalizations, or vaccine failure amid widespread population immunity from prior infections and boosters. Overall SARS-CoV-2 cases remain low, underscoring effective genomic monitoring; a VOC upgrade would require substantial shifts in transmissibility or public health impact.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트
외부 링크에 주의하세요.
외부 링크에 주의하세요.
자주 묻는 질문